Why did this ASX healthcare share just crash 70%?

This healthcare share has been dealt a major blow in the United States.

A worried man holds his head and look at his computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been a day to forget for the Pacific Edge Ltd (ASX: PEB) shareholders on Wednesday.

At one stage today, this ASX healthcare share was down as much as 71% to 11 cents.

And while the Pacific Edge share price has recovered a touch since then, it still remains down by almost 65% to 13.5 cents.

Why is this ASX healthcare share crashing deep into the red?

Investors have been rushing to the exits today after the cancer diagnostics company was dealt a massive blow in the United States.

According to the release, the company's Cxbladder tests in the US market will no longer be covered by Medicare from 17 July 2023.

This follows the finalisation of a Local Coverage Determination (LCD) by Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction for Pacific Edge's laboratory in Hershey Pennsylvania.

The release notes that the finalised LCD specifically notes the Cxbladder tests Triage, Detect, Monitor, Resolve and Detect+ as "not considered medically reasonable and necessary." This is the threshold required for coverage under the US Social Security Act.

What now?

While the company is exploring its legal options, as things stand, this LCD is expected to lead to a significant reduction in revenue.

Management points out that in the year ended March 2023, tests for Medicare and Medicare Advantage were ~60% of its US commercial tests. This generated ~$15.3 million of revenue or 77.3% of its total FY 2023 operating revenue. Post 17 July, all of these tests are expected to be impacted by this determination from Novitas.

The ASX healthcare share's CEO, Dr Peter Meintjes, wasn't happy with the decision. He said:

While Novitas appears to have reviewed all available evidence for Cxbladder, we believe that Novitas' analysis has sought to predominantly emphasize negative comments in Cxbladder publications.

We believe that focusing predominantly on only negative comments likely mischaracterizes issues or confounding factors with our evidence that were addressed in subsequent publications and routine commercial testing, while also dismissing the support Cxbladder receives from key opinion leading urologists, and the US patient advocacy group BCAN (Bladder Cancer Advocacy Network).

Importantly, urologists have identified the value for themselves and their patients as demonstrated by the record number of urologists using the test, 1,151 in FY23Q4, and the record growth in Cxbladder testing volume at 43% CAGR for the last two years.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »